Predicted to enable ion binding activity and protein kinase activity. Predicted to be involved in several processes, including intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; negative regulation of calcineurin-NFAT signaling cascade; and positive regulation of glycogen biosynthetic process. Predicted to be located in cytosol and nucleoplasm. Predicted to be part of ribonucleoprotein complex and ubiquitin ligase complex. Predicted to be active in cytoplasm; cytoskeleton; and nucleus. Orthologous to human DYRK2 (dual specificity tyrosine phosphorylation regulated kinase 2); PARTICIPATES IN p53 signaling pathway; INTERACTS WITH 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DYRK2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DYRK2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DYRK2 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol S] results in increased expression of DYRK2 mRNA
[Plant Extracts co-treated with Resveratrol] results in decreased expression of DYRK2 mRNA and [Plant Extracts co-treated with Resveratrol] results in increased expression of DYRK2 mRNA